drug_type
RELEVANT_DRUG
intervention_type
Biological (bispecific monoclonal antibody)
drug_description
An anti-CD22 × anti-CD28 costimulatory bispecific monoclonal antibody that binds CD22 on B cells and CD28 on T cells to deliver CD28 costimulation without independent T-cell activation; a costimulatory T-cell–engager.
nci_thesaurus_concept_id
C199616
nci_thesaurus_preferred_term
Anti-CD22/Anti-CD28 Bispecific Antibody REGN5837
nci_thesaurus_definition
A hinge-stabilized human immunoglobulin G4 (IgG4) bispecific antibody directed against both the tumor-associated antigen (TAA) CD22 and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD22/anti-CD28 bispecific antibody REGN5837 targets and binds to both CD28 expressed on T-cells and CD22 expressed on tumor cells, which crosslinks the T-cells to the tumor cells. This may result in the activation of a cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor cells. CD22 is exclusively expressed on B-cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Costimulatory bispecific IgG4 antibody that binds CD22 on B cells and CD28 on T cells to deliver CD28 costimulation without independent T-cell activation. By crosslinking T cells to CD22+ tumor cells, it provides CD28 costimulatory signaling in the context of TCR engagement, enhancing cytotoxic T-lymphocyte activation and killing of CD22-expressing B-cell malignancies.
drug_name
REGN5837
nct_id_drug_ref
NCT05685173